Horatiu Olteanu, Ph.D. - Publications

Affiliations: 
2003 The University of Nebraska - Lincoln, Lincoln, NE 
Area:
Biochemistry

40 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Olteanu H. Role of Flow Cytometry in the Diagnosis and Prognosis of Plasma Cell Myeloma. Surgical Pathology Clinics. 9: 101-16. PMID 26940271 DOI: 10.1016/j.path.2015.09.009  1
2015 Mboko WP, Olteanu H, Ray A, Xin G, Darrah EJ, Kumar SN, Kulinski JM, Cui W, Dittel BN, Gauld SB, Tarakanova VL. Tumor suppressor IRF-1 counteracts germinal center reaction driven by a cancer-associated gammaherpesvirus. Journal of Virology. PMID 26719266 DOI: 10.1128/JVI.02774-15  1
2015 Cogbill CH, Spears MD, Vantuinen P, Harrington AM, Olteanu H, Kroft SH. Morphologic and cytogenetic variables affect the flow cytometric recovery of plasma cell myeloma cells in bone marrow aspirates. International Journal of Laboratory Hematology. 37: 797-808. PMID 26224420 DOI: 10.1111/ijlh.12411  1
2012 Olteanu H, Harrington AM, Kroft SH. CD200 expression in plasma cells of nonmyeloma immunoproliferative disorders: clinicopathologic features and comparison with plasma cell myeloma. American Journal of Clinical Pathology. 138: 867-76. PMID 23161721 DOI: 10.1309/AJCP3TQR1TFHHGAS  1
2012 Olteanu H, Harrington AM, Kroft SH. Immunophenotypic stability of CD200 expression in plasma cell myeloma. American Journal of Clinical Pathology. 137: 1013-4. PMID 22586062 DOI: 10.1309/AJCP8TF3WUIWLZHU  1
2012 Harrington AM, Olteanu H, Kroft SH. A dissection of the CD45/side scatter "blast gate". American Journal of Clinical Pathology. 137: 800-4. PMID 22523220 DOI: 10.1309/AJCPN4G1IZPABRLH  1
2012 Vaughan J, Harrington AM, Hari PN, Kroft SH, Olteanu H. Immunophenotypic stability of Sézary cells by flow cytometry: usefulness of flow cytometry in assessing response to and guiding alemtuzumab therapy. American Journal of Clinical Pathology. 137: 403-11. PMID 22338052 DOI: 10.1309/AJCP7QHH5XASTJPL  1
2012 Olteanu H, Harrington AM, George B, Hari PN, Bredeson C, Kroft SH. High prevalence of Dapsone-induced oxidant hemolysis in North American SCT recipients without glucose-6-phosphate-dehydrogenase deficiency Bone Marrow Transplantation. 47: 399-403. PMID 21478917 DOI: 10.1038/bmt.2011.83  1
2011 Horna P, Olteanu H, Kroft SH, Harrington AM. Flow cytometric analysis of surface light chain expression patterns in B-cell lymphomas using monoclonal and polyclonal antibodies. American Journal of Clinical Pathology. 136: 954-9. PMID 22095382 DOI: 10.1309/AJCP3C2QZZBPTMLB  1
2011 Buonaccorsi JN, Kroft SH, Harrington AM, VanTuinen P, Olteanu H. Clinicopathologic analysis of the impact of CD23 expression in plasma cell myeloma with t(11;14)(q13;q32). Annals of Diagnostic Pathology. 15: 385-8. PMID 21724429 DOI: 10.1016/j.anndiagpath.2011.04.004  1
2011 Olteanu H. Case Study Interpretation--Houston: Case 2. Classical Hodgkin lymphoma. Cytometry. Part B, Clinical Cytometry. 80: 258-60. PMID 21638769 DOI: 10.1002/cyto.b.20598  1
2011 Spears MD, Olteanu H, Kroft SH, Harrington AM. The immunophenotypic stability of plasma cell myeloma by flow cytometry International Journal of Laboratory Hematology. 33: 483-491. PMID 21470371 DOI: 10.1111/j.1751-553X.2011.01317.x  1
2011 Harrington AM, Olteanu H, Kroft SH, Eshoa C. The unique immunophenotype of double-hit lymphomas. American Journal of Clinical Pathology. 135: 649-50. PMID 21411790 DOI: 10.1309/AJCPL11MAHISIJBQ  1
2011 Olteanu H, Harrington AM, Hari P, Kroft SH. CD200 expression in plasma cell myeloma. British Journal of Haematology. 153: 408-11. PMID 21275968 DOI: 10.1111/j.1365-2141.2010.08555.x  1
2011 Olteanu H, Fenske TS, Harrington AM, Szabo A, He P, Kroft SH. CD23 expression in follicular lymphoma: clinicopathologic correlations. American Journal of Clinical Pathology. 135: 46-53. PMID 21173123 DOI: 10.1309/AJCP27YWLIQRAJPW  1
2011 Torgerson S, Olteanu H, Tinguely M, Fenske TS. Central nervous system Hodgkin lymphoma: case report and review of the literature. Journal of Neuro-Oncology. 102: 329-34. PMID 20676729 DOI: 10.1007/s11060-010-0320-8  1
2010 Harrington A, Olteanu H, Kroft S. The specificity of immunophenotypic alterations in blasts in nonacute myeloid disorders. American Journal of Clinical Pathology. 134: 749-61. PMID 20959658 DOI: 10.1309/AJCPFNF5MN1GDWKU  1
2010 Spears MD, Harrington AM, Kroft SH, Olteanu H. Immunophenotypic stability of T-cell large granular lymphocytic leukaemia by flow cytometry. British Journal of Haematology. 151: 97-9. PMID 20636433 DOI: 10.1111/j.1365-2141.2010.08307.x  1
2010 Harrington AM, Currey A, Olteanu H, Kroft SH. Persistent localized bone marrow aplasia after radiotherapy with preserved peripheral counts: a study of 8 cases. Annals of Diagnostic Pathology. 14: 168-72. PMID 20471561 DOI: 10.1016/j.anndiagpath.2010.02.006  1
2010 Olteanu H, Harrington AM, Ramirez S, Kroft SH, Hari P. Efficacy and safety of long-term (>7 year) alemtuzumab therapy for refractory T-cell large granular lymphocytic leukaemia. British Journal of Haematology. 150: 480-1. PMID 20456357 DOI: 10.1111/j.1365-2141.2010.08218.x  1
2010 Plaza JA, Ortega P, Lynott J, Mullane M, Kroft S, Olteanu H. CD8-positive primary cutaneous anaplastic large T-cell lymphoma (PCALCL): case report and review of this unusual variant of PCALCL. The American Journal of Dermatopathology. 32: 489-91. PMID 20442639 DOI: 10.1097/DAD.0b013e3181c57ec2  1
2010 Olteanu H, Schur BC, Bredeson C, Atallah E, Kroft SH. Expression of natural killer receptors in T- and NK-cells: comparison of healthy individuals, patients with prior stem cell transplant, and patients undergoing chemotherapy. Leukemia & Lymphoma. 51: 481-7. PMID 20141431 DOI: 10.3109/10428190903552120  1
2010 Morice WG, Jevremovic D, Olteanu H, Roden A, Nowakowski G, Kroft S, Hanson CA, Kurtin PJ. Chronic lymphoproliferative disorder of natural killer cells: a distinct entity with subtypes correlating with normal natural killer cell subsets. Leukemia. 24: 881-4. PMID 20111066 DOI: 10.1038/leu.2009.304  1
2010 Olteanu H, Karandikar NJ, Eshoa C, Kroft SH. Laboratory findings in CD4(+) large granular lymphocytoses International Journal of Laboratory Hematology. 32. PMID 20089001 DOI: 10.1111/j.1751-553X.2008.01109.x  1
2010 Walters M, Olteanu H, Van Tuinen P, Kroft SH. CD23 expression in plasma cell myeloma is specific for abnormalities of chromosome 11, and is associated with primary plasma cell leukaemia in this cytogenetic sub-group. British Journal of Haematology. 149: 292-3. PMID 20064156 DOI: 10.1111/j.1365-2141.2009.08042.x  1
2009 Olteanu H, Harrington A, Kroft SH. Sperm in peritoneal fluid from a man with ascites: a case report. Cases Journal. 2: 192. PMID 19946502 DOI: 10.1186/1757-1626-2-192  1
2009 Parker SM, Olteanu H, Vantuinen P, Lawton CA, Schultz CJ, Christians KK, Fenske TS. Follicular lymphoma transformation to dual translocated Burkitt-like lymphoma: improved disease control associated with radiation therapy. International Journal of Hematology. 90: 616-22. PMID 19937165 DOI: 10.1007/s12185-009-0444-9  1
2009 Olteanu H, Downes KA, Patel J, Praprotnik D, Sarode R. Warfarin does not interfere with lupus anticoagulant detection by dilute Russell's viper venom time. Clinical Laboratory. 55: 138-42. PMID 19462936  1
2008 Olteanu H, Wang HY, Chen W, McKenna RW, Karandikar NJ. Immunophenotypic studies of monoclonal gammopathy of undetermined significance. Bmc Clinical Pathology. 8: 13. PMID 19040735 DOI: 10.1186/1472-6890-8-13  1
2007 Dyszkiewicz-Korpanty A, Olteanu H, Frenkel EP, Sarode R. Clopidogrel anti-platelet effect: an evaluation by optical aggregometry, impedance aggregometry, and the platelet function analyzer (PFA-100). Platelets. 18: 491-6. PMID 17852774 DOI: 10.1080/09537100701280654  1
2006 Olteanu H, Karandikar NJ, McKenna RW, Xu Y. Differential usefulness of various markers in the flow cytometric detection of paroxysmal nocturnal hemoglobinuria in blood and bone marrow. American Journal of Clinical Pathology. 126: 781-8. PMID 17050075 DOI: 10.1309/AT9Y-6WR0-3PX1-K228  1
2006 Olteanu H, Xu Y. The use of flow cytometry in diagnosis of paroxysmal nocturnal hemoglobinuria Laboratory Medicine. 37: 498-502. DOI: 10.1309/NAAH-5J8D-V43C-0H7N  1
2005 Olteanu H, Gerber D, Partridge K, Sarode R. Acute hemolytic transfusion reaction secondary to anti-Fy3. Immunohematology / American Red Cross. 21: 48-52. PMID 15981343  1
2005 Zhang W, Braun A, Bauman Z, Olteanu H, Madzelan P, Banerjee R. Expression profiling of homocysteine junction enzymes in the NCI60 panel of human cancer cell lines. Cancer Research. 65: 1554-60. PMID 15735045 DOI: 10.1158/0008-5472.CAN-04-1554  1
2004 Leal NA, Olteanu H, Banerjee R, Bobik TA. Human ATP:Cob(I)alamin adenosyltransferase and its interaction with methionine synthase reductase. The Journal of Biological Chemistry. 279: 47536-42. PMID 15347655 DOI: 10.1074/jbc.M405449200  1
2004 Olteanu H, Wolthers KR, Munro AW, Scrutton NS, Banerjee R. Kinetic and thermodynamic characterization of the common polymorphic variants of human methionine synthase reductase. Biochemistry. 43: 1988-97. PMID 14967039 DOI: 10.1021/bi035910i  1
2004 Waly M, Olteanu H, Banerjee R, Choi SW, Mason JB, Parker BS, Sukumar S, Shim S, Sharma A, Benzecry JM, Power-Charnitsky VA, Deth RC. Activation of methionine synthase by insulin-like growth factor-1 and dopamine: a target for neurodevelopmental toxins and thimerosal. Molecular Psychiatry. 9: 358-70. PMID 14745455 DOI: 10.1038/sj.mp.4001476  1
2003 Olteanu H, Banerjee R. Redundancy in the pathway for redox regulation of mammalian methionine synthase: reductive activation by the dual flavoprotein, novel reductase 1. The Journal of Biological Chemistry. 278: 38310-4. PMID 12871938 DOI: 10.1074/jbc.M306282200  1
2002 Olteanu H, Munson T, Banerjee R. Differences in the efficiency of reductive activation of methionine synthase and exogenous electron acceptors between the common polymorphic variants of human methionine synthase reductase. Biochemistry. 41: 13378-85. PMID 12416982 DOI: 10.1021/bi020536s  1
2001 Olteanu H, Banerjee R. Human methionine synthase reductase, a soluble P-450 reductase-like dual flavoprotein, is sufficient for NADPH-dependent methionine synthase activation. The Journal of Biological Chemistry. 276: 35558-63. PMID 11466310 DOI: 10.1074/jbc.M103707200  1
Show low-probability matches.